Super Bowl Ad Spotlights Weight-Loss Drug Copycats

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
What is compounded semaglutide and is it safe? The weight loss drugs Hims & Hers is selling, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
The weight loss drug dilemma no one wants to talk about
GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most Americans.
Drug industry groups target Hims & Hers Super Bowl ad touting weight loss drug
Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
What’s the Mechanism Behind Behavioral Side Effects of Weight Loss Drugs?
GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.
Weight Loss Drug Super Bowl Ad Raises Questions About Compounded Vs. Branded Meds
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.
Hims & Hers Super Bowl commercial: Ad draws ire from drug industry
Hims & Hers makes its Super Bowl commercial debut in 2025 with a spot for the telehealth company's weight loss medications. Set to the "This Is America" by Childish Gambino (Donald Glover), the commercial calls out weight loss prescriptions and the weight-loss industry that "feeds on our failure.
Hims & Hers aired a Super Bowl ad for weight loss drugs. It alarmed health experts and senators.
During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.” But before the 60-second spot was played on Fox Sunday night, the ad — which deems obesity “America’s deadliest epidemic,
Super Bowl ad for copycat weight loss drugs stokes pharma power debate
Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting event.
Rolling Out6h
Illegal weight loss drug sales flourish on social media
Discover why people risk buying Ozempic and similar weight loss medications through social media, the devastating consequences, and legitimate ways to treatment ...
Popular weight-loss drugs show promise in reducing kidney disease complications and mortality
A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...
News Medical12h
What's Next for Semaglutide? Beyond Diabetes and Weight Loss
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Cosmetic surgeons try to correct 'Ozempic face' for weight-loss drug users
Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...
WDRB13h
The 2 sides of Ozempic — weight loss success stories and health nightmares in Kentucky
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...